Altered Folate Homeostasis in Children with Down Syndrome: A Potential Basis for Enhanced Methotrexate Toxicity

J Pediatr. 2020 Jun:221:235-239. doi: 10.1016/j.jpeds.2020.01.032. Epub 2020 Feb 25.

Abstract

Methotrexate is used to treat autoimmune and oncologic diseases in children with Down syndrome. However, increased methotrexate-related toxicity is reported in this population. We evaluated differences in the concentrations and distribution of erythrocyte folates in children with Down syndrome as a potential basis for this enhanced toxicity.

Keywords: Down syndrome; folates; pediatrics; precision medicine; toxicity.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Child, Preschool
  • Down Syndrome / blood*
  • Erythrocytes / metabolism
  • Folic Acid / administration & dosage
  • Folic Acid / blood*
  • Homeostasis*
  • Humans
  • Methotrexate / pharmacology
  • Methotrexate / toxicity
  • Pilot Projects
  • Sampling Studies
  • Vitamin B Complex / administration & dosage

Substances

  • Vitamin B Complex
  • Folic Acid
  • Methotrexate